Maksikold

Maksikold – drug for a symptomatic treatment of acute respiratory diseases.

Form of release and structure

• Tablets, film coated: oval, from two parties convex, pinkish-orange color, from risky; on cross section of pinkish-orange color with orange and white impregnations (on 2, 10 or 12 pieces in strip planimetric packagings, in a cardboard pack 1 or 2 packagings);
• Powder for preparation of solution for intake: crystal, light yellow or pink (existence of white crystals and easily breaking up lumps is possible), with a specific smell; ready solution – opalescent, light yellow color with a characteristic smell of orange or a lemon or pink color with a characteristic smell of raspberry (on 5 g in the bags made of the combined material in a pack of cardboard 5, 10 or 50 bags).

Active ingredients in 1 tablet:

• Paracetamol – 500 mg;
• Ascorbic acid – 30 mg;
• Phenylephrinum a hydrochloride – 10 mg.

Active ingredients in 1 bag of powder:

• Paracetamol – 750 mg;
• Ascorbic acid – 60 mg;
• Phenylephrinum a hydrochloride – 10 mg.

Additional inactive components of tablets:

• Structure of a kernel: magnesium silicate, hypro rod (hydroxypropyl cellulose), talc, calcium hydrophosphate, croscarmellose sodium, ethyl cellulose, dye sunset yellow;
• Structure of a cover: titanium dioxide, talc, hypro rod, gipromelloza, dye sunset yellow.

Powder excipients: potato starch, citric acid, lactose, sodium saccharin, silicon dioxide colloid, sodium citrate, fragrance, dye quinolinic yellow (powder with taste of orange and a lemon) or dye acid red (powder with taste of raspberry).

Indications to use

Maksikold – drug for symptomatic therapy of the infectious and inflammatory diseases (including flu and acute respiratory viral infections) which are followed by a fever, the increased body temperature, a nose congestion, nose bosom, throat, muscles and bones pain, a headache.

Contraindications

Absolute:

• Hyperthyroidism (including a thyrotoxicosis);
• Arterial hypertension;
• Heart diseases (tachyarrhythmias, an acute myocardial infarction, the expressed stenosis of the mouth of an aorta);
• Closed-angle glaucoma;
• Prostate hyperplasia;
• The expressed renal/liver failure;
• Alcoholism;
• Children's age up to 9 years (or body weight is less than 30 kg) – for tablets, up to 12 years – for powder;
• Simultaneous use of other drugs containing paracetamol;
• Concomitant use of monoamine oxidase inhibitors (and also 14 days after their cancellation), beta adrenoblockers, tricyclic antidepressants;
• Hypersensitivity to drug components.

Relative:

• High-quality hyperbilirubinemias;
• Deficit glyukozo-6-fosfatdegidrogenazy;
• Pregnancy;
• Lactation;
• Advanced age.

Route of administration and dosage

Tablets, film coated
Maksikold it is necessary to accept inside, swallowing of tablets entirely and washing down with water, to food or in 1-2 hours after meal.

The recommended doses:

• Adults and teenagers are more senior than 12 years (with body weight more than 40 kg): on 1-2 tablets each 4-6 hours, but no more than 4 times a day;
• Children of 9-12 years (with the body weight of 30-40 kg): on 1 tablet each 4-6 hours, but no more than 4 times a day.

Powder for preparation of solution for intake
Drug is accepted inside. For this purpose it is necessary to pour out contents of 1 package in a cup, to fill in with hot water and to stir before full dissolution of powder. To accept hot.

The recommended doses:

• Adults: on 1 package each 4-6 hours, but no more than 4 times a day;
• Teenagers are more senior than 12 years: on 1 package each 6 hours, but no more than 3 times a day.

Regardless of the appointed dosage form Maksikolda should not exceed duration of treatment 3 days if drug is used as an antipyretic, and 5 days – as anesthetic. Need of more prolonged treatment is defined individually by the doctor.

Side effects

• Allergic reactions: rash, urticaria, dermahemia, Quincke's disease;
• The side effects caused by paracetamol: hemopoiesis disturbances (methemoglobinemia, thrombocytopenia, anemia);
• The side effects caused by Phenylephrinum: an asthma, irritability, bradycardia, heartbeat, stenocardia, tachycardia, motive concern, increase or decrease in the ABP, ventricular arrhythmia (especially at reception of high doses), a headache, nausea or vomiting, allergic reactions;
• The side effects caused by ascorbic acid: irritation of a mucous membrane of digestive tract, thrombocytosis, erythropenia, hypopotassemia, neutrophylic leukocytosis, glucosuria, oppression of function of the insulyarny device of a pancreas; at long reception of high doses – diarrhea, an ultseration of a mucous membrane of digestive tract, nausea, vomiting, hyperacid gastritis, decrease in permeability of capillaries (increase in arterial pressure, deterioration in a trophicity of fabrics, mikroangiopatiya, hypercoagulation).

At prolonged use of Maksikold the risk of increase in excitability of the central nervous system, emergence of a headache and sleeplessness, development of renal failures increases in the doses considerably exceeding recommended (are shown by the hyperoxaluria moderated by a pollakiuria, damage of the glomerular device of kidneys, a nephrolithiasis).

Special instructions

Before Maksikold's reception should consult with the doctor patients who accept Colestyraminum, домперидон or Metoclopramidum (as change of speed of absorption of paracetamol is possible), or anticoagulants (since their effect increases).

It must be kept in mind that during treatment drug distorts results of laboratory tests on definition of concentration of uric acid and glucose in a blood plasma.

At prolonged treatment (more than 5-7 days) it is necessary to control function of a liver and a condition of peripheral blood.

During Maksikold's reception it is necessary to refrain from alcohol intake since the risk of toxic damage of a liver increases.

Negative impact on the speed of reactions and ability to concentration drug does not pay attention.

Medicinal interaction

Paracetamol:

• In high doses strengthens effect of anticoagulants;
• Reduces efficiency of uricosuric and diuretic drugs.

Ascorbic Acid (AA):

• Reduces efficiency of indirect anticoagulants, heparin and antipsychotic drugs (neuroleptics) which are derivatives of a fenotiazin;
• Increases the general clearance of ethanol reducing concentration of joint stock company;
• Reduces a canalicular reabsorption of tricyclic antidepressants and amphetamine;
• Improves absorption of iron preparations in intestines;
• Reduces concentration in blood of oral contraceptives;
• Slows down removal by kidneys of acids;
• Reduces chronotropic action of an izoprenalin;
• Strengthens removal of the means having alkali reaction (including alkaloids);
• Increases risk of development of a crystalluria at treatment by streptocides of short action or salicylates;
• Increases concentration in blood of tetracyclines and benzylpenicillin;
• In high doses increases removal of a meksiletin kidneys;
• At prolonged use or reception in high doses can interfere with interaction of Disulfiramum with ethanol.

Phenylephrinum:

• Reduces anti-anginal effect of nitrates;
• Reduces hypotensive effect of diuretics and anti-hypertensive means (including a mekamilamina, Methyldopums, a guanetidina, a guanadrela).

Possible reactions of interaction in case of simultaneous use of Maksikold with other medicines:

• Monoamine oxidase inhibitors, sedatives, ethanol: their effects amplify;
• Ethanol, hepatotoxic drugs, inductors of enzymes of a microsomal oxidation in a liver (for example, barbiturates, phenylbutazone, rifampicin, tricyclic antidepressants, Phenytoinum): the risk of development of a hepatotoxic action of paracetamol increases;
• The barbiturates accepted for a long time: efficiency of paracetamol decreases;
• Metoclopramidum, домперидон: paracetamol absorption speed increases;
• Colestyraminum: paracetamol absorption speed decreases;
• Inhibitors of enzymes of a microsomal oxidation (for example, Cimetidinum): the risk of a hepatotoxic action of paracetamol decreases;
• Ethanol: the probability of development of acute pancreatitis increases;
• Salicylates (at reception of high doses of paracetamol): the risk of development of cancer of bladder or kidney increases;
• Diflunisal: plasma concentration of paracetamol and risk of development of a hepatotoxic increases;
• Miyelotoksichny means: manifestations of a gematotoksichnost of paracetamol amplify;
• Monoamine oxidase inhibitors (including селегилин, Procarbazinum, furasolidone), tricyclic antidepressants, ergot alkaloids, adrenostimulyator, methylphenidate, oxytocin: vasoconstrictive action and an aritmogennost of Phenylephrinum amplifies;
• Reserpinum: the risk of arterial hypertension increases;
• Thyroid hormones: the effect of Phenylephrinum and the related risk of emergence of coronary insufficiency amplifies (especially at patients with coronary atherosclerosis);
• Non-steroidal anti-inflammatory drugs: the risk of development of a "analgetic" nephropathy, renal papillary necrosis and approach of an end-stage of a renal failure increases;
• Inhalation anesthetics (including halothane, энфлуран, метоксифлуран, изофлуран, chloroform): the probability of developing of heavy atrial and ventricular arrhythmia increases;
• Acetylsalicylic acid (ASK): removal of joint stock company with urine increases, removal of ASK decreases;
• Oral contraceptives, ASK, alkaline drinks, fresh juice: absorption and digestion of ascorbic acid decreases;
• Primidonum, barbiturates: removal of ascorbic acid with urine amplifies;
• Glucocorticoids, salicylates, calcium chloride, drugs of a quinolinic row: at prolonged use reserves of ascorbic acid are exhausted;
• Antipsychotic and protivoparkinsonichesky means, antidepressants derivative of a fenotiazin: the risk of emergence of dryness in a mouth, ischurias, a lock increases;
• Glucocorticosteroids: the risk of development of glaucoma increases;
• Halothane: the probability of development of ventricular arrhythmia increases;
• Guanetidin: amplifies alpha адреностимулирующий effect of Phenylephrinum;
• Tricyclic antidepressants: the sympathomimetic effect of Phenylephrinum amplifies.

Terms and storage conditions

To store at a temperature up to 25 ºС in the dry, protected from children place.

Period of validity – 2 years.